Novartis AG (SIX: NOVN.SW) Stock Competitors & Peer Comparison

Novartis AG (SIX: NOVN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN.SW stands at 218.8B. In comparison, LLY.SW has a market cap of 851.6B. Regarding current trading prices, NOVN.SW is priced at CHF 115.10 on the SIX, while LLY.SW trades at CHF 955.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN.SW currently has a P/E ratio of 16.75, whereas LLY.SW's P/E ratio is 37.94. In terms of profitability, NOVN.SW's ROE is +0.30%, compared to LLY.SW's ROE of +0.93%. Regarding short-term risk, NOVN.SW is more volatile compared to LLY.SW. This indicates higher risk in terms of short-term price fluctuations for NOVN.SW.Check LLY.SW's competition here

Novartis AG (SIX: NOVN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN.SW stands at 218.8B. In comparison, JNJ.SW has a market cap of 535.1B. Regarding current trading prices, NOVN.SW is priced at CHF 115.10 on the SIX, while JNJ.SW trades at CHF 222.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN.SW currently has a P/E ratio of 16.75, whereas JNJ.SW's P/E ratio is 25.26. In terms of profitability, NOVN.SW's ROE is +0.30%, compared to JNJ.SW's ROE of +0.26%. Regarding short-term risk, NOVN.SW is more volatile compared to JNJ.SW. This indicates higher risk in terms of short-term price fluctuations for NOVN.SW.Check JNJ.SW's competition here

Novartis AG (SIX: NOVN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN.SW stands at 218.8B. In comparison, RO.SW has a market cap of 286B. Regarding current trading prices, NOVN.SW is priced at CHF 115.10 on the SIX, while RO.SW trades at CHF 364.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN.SW currently has a P/E ratio of 16.75, whereas RO.SW's P/E ratio is 21.87. In terms of profitability, NOVN.SW's ROE is +0.30%, compared to RO.SW's ROE of +0.37%. Regarding short-term risk, NOVN.SW is less volatile compared to RO.SW. This indicates lower risk in terms of short-term price fluctuations for NOVN.SW.Check RO.SW's competition here

Novartis AG (SIX: NOVN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN.SW stands at 218.8B. In comparison, ROP.SW has a market cap of 284B. Regarding current trading prices, NOVN.SW is priced at CHF 115.10 on the SIX, while ROP.SW trades at CHF 356.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN.SW currently has a P/E ratio of 16.75, whereas ROP.SW's P/E ratio is 18.34. In terms of profitability, NOVN.SW's ROE is +0.30%, compared to ROP.SW's ROE of +0.37%. Regarding short-term risk, NOVN.SW is less volatile compared to ROP.SW. This indicates lower risk in terms of short-term price fluctuations for NOVN.SW.Check ROP.SW's competition here

Novartis AG (SIX: NOVN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN.SW stands at 218.8B. In comparison, ROG.SW has a market cap of 256.6B. Regarding current trading prices, NOVN.SW is priced at CHF 115.10 on the SIX, while ROG.SW trades at CHF 322.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN.SW currently has a P/E ratio of 16.75, whereas ROG.SW's P/E ratio is 20.11. In terms of profitability, NOVN.SW's ROE is +0.30%, compared to ROG.SW's ROE of +0.41%. Regarding short-term risk, NOVN.SW is less volatile compared to ROG.SW. This indicates lower risk in terms of short-term price fluctuations for NOVN.SW.Check ROG.SW's competition here

Novartis AG (SIX: NOVN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN.SW stands at 218.8B. In comparison, GILD.SW has a market cap of 143.2B. Regarding current trading prices, NOVN.SW is priced at CHF 115.10 on the SIX, while GILD.SW trades at CHF 115.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN.SW currently has a P/E ratio of 16.75, whereas GILD.SW's P/E ratio is -290.93. In terms of profitability, NOVN.SW's ROE is +0.30%, compared to GILD.SW's ROE of -0.17%. Regarding short-term risk, NOVN.SW is more volatile compared to GILD.SW. This indicates higher risk in terms of short-term price fluctuations for NOVN.SW.Check GILD.SW's competition here

Novartis AG (SIX: NOVN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN.SW stands at 218.8B. In comparison, GSK.SW has a market cap of 101.6B. Regarding current trading prices, NOVN.SW is priced at CHF 115.10 on the SIX, while GSK.SW trades at CHF 19.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN.SW currently has a P/E ratio of 16.75, whereas GSK.SW's P/E ratio is 18.76. In terms of profitability, NOVN.SW's ROE is +0.30%, compared to GSK.SW's ROE of +0.38%. Regarding short-term risk, NOVN.SW is not fully comparable compared to GSK.SW. This indicates unavailable risk data in terms of short-term price fluctuations for NOVN.SW.Check GSK.SW's competition here

Novartis AG (SIX: NOVN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN.SW stands at 218.8B. In comparison, BMY.SW has a market cap of 87.7B. Regarding current trading prices, NOVN.SW is priced at CHF 115.10 on the SIX, while BMY.SW trades at CHF 52.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN.SW currently has a P/E ratio of 16.75, whereas BMY.SW's P/E ratio is 10.13. In terms of profitability, NOVN.SW's ROE is +0.30%, compared to BMY.SW's ROE of +0.45%. Regarding short-term risk, NOVN.SW is more volatile compared to BMY.SW. This indicates higher risk in terms of short-term price fluctuations for NOVN.SW.Check BMY.SW's competition here

Novartis AG (SIX: NOVN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN.SW stands at 218.8B. In comparison, BAYN.SW has a market cap of 45.5B. Regarding current trading prices, NOVN.SW is priced at CHF 115.10 on the SIX, while BAYN.SW trades at CHF 46.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN.SW currently has a P/E ratio of 16.75, whereas BAYN.SW's P/E ratio is 10.33. In terms of profitability, NOVN.SW's ROE is +0.30%, compared to BAYN.SW's ROE of -0.06%. Regarding short-term risk, NOVN.SW is more volatile compared to BAYN.SW. This indicates higher risk in terms of short-term price fluctuations for NOVN.SW.Check BAYN.SW's competition here

Novartis AG (SIX: NOVN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN.SW stands at 218.8B. In comparison, BIIB.SW has a market cap of 20.8B. Regarding current trading prices, NOVN.SW is priced at CHF 115.10 on the SIX, while BIIB.SW trades at CHF 141.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN.SW currently has a P/E ratio of 16.75, whereas BIIB.SW's P/E ratio is 11.19. In terms of profitability, NOVN.SW's ROE is +0.30%, compared to BIIB.SW's ROE of +0.05%. Regarding short-term risk, NOVN.SW is more volatile compared to BIIB.SW. This indicates higher risk in terms of short-term price fluctuations for NOVN.SW.Check BIIB.SW's competition here